Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials
- 1 April 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Coronary Artery Disease
- Vol. 14 (2), 171-179
- https://doi.org/10.1097/00019501-200304000-00010
Abstract
The objective of this meta-analysis was to evaluate the efficacy and tolerance of the metabolic agent trimetazidine (TMZ), both in monotherapy and in combination with other antianginal agents, in the treatment of stable angina pectoris. A search of literature published between 1985 and 2001 was performed on computerized databases (MEDLINE and EMBASE). Only double-blind, randomized, controlled trials were included in this meta-analysis. Patients had to be treated for at least 2 weeks. Four parameters were selected, one clinical parameter (number of weekly angina attacks) and three ergometric parameters (time to 1 mm ST-segment depression, total work and exercise duration at peak exercise). They were evaluated at baseline and at the end of the treatment period.The quality of the trials was assessed on specific methodological criteria. Standard statistical methods, pooled odds ratio and 95% confidence intervals for subjective symptoms and pooled z and P for objective symptoms, were used. Twelve clinical studies meeting our criteria were analyzed. Results showed that TMZ significantly reduced the number of weekly angina attacks in coronary patients and improved time to 1 mm segment depression and total work at peak exercise, while exercise duration at peak exercise showed a trend toward improvement (P = 0.09). This meta-analysis confirms the efficacy of TMZ in the treatment of stable angina, compared with placebo or conventional antianginal agent, as well as in monotherapy or in combination with conventional antianginal agents. TMZ is well tolerated in monotherapy as well as in combination.Keywords
This publication has 25 references indexed in Scilit:
- Combination treatment in stable effort angina using trimetazidine and metoprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II)European Heart Journal, 2001
- The effect of trimetazidine in the treatment of microvascular anginaInternational Journal of Angiology, 1999
- Safety of Nifedipine in Angina PectorisHypertension, 1999
- TrimetazidineDrugs, 1999
- Management of stable angina pectoris: Recommendations of the Task Force of the European Society of CardiologyEuropean Heart Journal, 1997
- Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable AnginaClinical Drug Investigation, 1997
- Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris results of the international multicenter angina exercise (IMAGE) studyJournal of the American College of Cardiology, 1996
- Total Ischaemic Burden European Trial (TIBET): Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable anginaEuropean Heart Journal, 1996
- Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.British Journal of Clinical Pharmacology, 1994
- Combined Beta-Adrenergic and Calcium-Entry Blockade in Angina PectorisNew England Journal of Medicine, 1989